The A-FABP Nexus in the Neurovascular Unit: Bridging Endothelial Barrier Breakdown and Microglial Lipotoxicity in Ischemic Stroke.
- 1College of Traditional Chinese Medicine, Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, 830017, People's Republic of China.
- 2Key Laboratory of Famous Doctors, Famous Prescriptions and Characteristic Formulas in Xinjiang, Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, 830017, People's Republic of China.
- 3Institute of Traditional Chinese Medicine, Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, 830017, People's Republic of China.
Abstract
Ischemic stroke is a neurological cerebrovascular event characterized by highly complex, spatiotemporally dynamic pathophysiological processes. In recent years, stroke research has shifted from early isolated neuroprotection to the systematic investigation of the multidimensional homeostasis of the entire neurovascular unit (NVU). Within this complex pathological network, neuroinflammation mediated by cerebral lipid metabolic dysregulation has gradually emerged as an important contributor to NVU dysfunction and post-stroke secondary injury. Among various lipid chaperones, adipocyte fatty acid-binding protein (A-FABP) has attracted increasing attention because of its involvement in metabolic dysregulation, vascular injury, and neuroinflammation. This review comprehensively examines the emerging evidence for the multifaceted involvement of A-FABP in ischemic stroke. In the hyperacute phase, A-FABP acts as a potent endothelial disruptor, compromising the integrity of the blood-brain barrier (BBB) by activating MMP-9; Beyond this established vascular mechanism, findings from other experimental contexts suggest that A-FABP may also contribute to microglial lipid dysregulation and associated inflammatory responses, providing a potential mechanistic link between vascular injury and immune-metabolic dysfunction within the NVU. Preclinical studies further indicate that pharmacological inhibition or neutralization of A-FABP can attenuate ischemic brain injury; however, its therapeutic efficacy and safety in patients with ischemic stroke remain to be established. This review provides an in-depth analysis of the dynamic balance of the spatiotemporal effects of A-FABP, further highlighting its core value as a biomarker for poor stroke prognosis and a highly promising therapeutic target. It also examines current translational bottlenecks, including phase-specific intervention windows, applicability across different stroke subtypes, unresolved mechanisms of NVU crosstalk, and pharmacological optimization, aiming to provide directions for future investigation of A-FABP within the stroke immune-metabolic network.
Related
- INPP5D/SHIP1 in Alzheimer's Disease: Linking Microglial Substrate Handling to Neuroinflammation and Neurovascular Dysfunction.
- Breakdown of adipocyte-endothelial communication as a driver of adipose tissue dysfunction in obesity
- Tangerine Peel Polysaccharide Alleviates High-Fat Diet-Induced Renal Lipotoxicity in Association with Gut Microbiota Remodeling in Mice
- Phytochemical Screening and Protective Effects of Hancornia speciosa Leaf Extract Against Fatty Acid-Induced Lipotoxicity in HepG2 Cells
- Cyanidin-3-O-Glucoside in Anthocyanin-Rich Fraction Combined with Atorvastatin Mitigates Kidney Injury via Attenuating Renal Lipotoxicity and Oxidative Stress and Preserving Mitochondrial Function in Obese Rats
BibTeX
@article{ma2026afabp,
title = {{The A-FABP Nexus in the Neurovascular Unit: Bridging Endothelial Barrier Breakdown and Microglial Lipotoxicity in Ischemic Stroke.}},
author = {Wen-Yu Ma and Lan Yao and Wei Lan},
journal = {Journal of inflammation research},
year = {2026},
month = oct,
doi = {10.2147/jir.s635848},
url = {https://europepmc.org/article/MED/42928899},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - The A-FABP Nexus in the Neurovascular Unit: Bridging Endothelial Barrier Breakdown and Microglial Lipotoxicity in Ischemic Stroke.
AU - Wen-Yu Ma
AU - Lan Yao
AU - Wei Lan
PY - 2026
DA - 2026/10/21
JO - Journal of inflammation research
DO - 10.2147/jir.s635848
UR - https://europepmc.org/article/MED/42928899
AB - Ischemic stroke is a neurological cerebrovascular event characterized by highly complex, spatiotemporally dynamic pathophysiological processes. In recent years, stroke research has shifted from early isolated neuroprotection to the systematic investigation of the multidimensional homeostasis of the entire neurovascular unit (NVU). Within this complex pathological network, neuroinflammation mediated by cerebral lipid metabolic dysregulation has gradually emerged as an important contributor to NVU dysfunction and post-stroke secondary injury. Among various lipid chaperones, adipocyte fatty acid-binding protein (A-FABP) has attracted increasing attention because of its involvement in metabolic dysregulation, vascular injury, and neuroinflammation. This review comprehensively examines the emerging evidence for the multifaceted involvement of A-FABP in ischemic stroke. In the hyperacute phase, A-FABP acts as a potent endothelial disruptor, compromising the integrity of the blood-brain barrier (BBB) by activating MMP-9; Beyond this established vascular mechanism, findings from other experimental contexts suggest that A-FABP may also contribute to microglial lipid dysregulation and associated inflammatory responses, providing a potential mechanistic link between vascular injury and immune-metabolic dysfunction within the NVU. Preclinical studies further indicate that pharmacological inhibition or neutralization of A-FABP can attenuate ischemic brain injury; however, its therapeutic efficacy and safety in patients with ischemic stroke remain to be established. This review provides an in-depth analysis of the dynamic balance of the spatiotemporal effects of A-FABP, further highlighting its core value as a biomarker for poor stroke prognosis and a highly promising therapeutic target. It also examines current translational bottlenecks, including phase-specific intervention windows, applicability across different stroke subtypes, unresolved mechanisms of NVU crosstalk, and pharmacological optimization, aiming to provide directions for future investigation of A-FABP within the stroke immune-metabolic network.
SN - 1178-7031
ER -